Ataxia Telangiectasia

Neurology
5
Pipeline Programs
3
Companies
4
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
2
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

U
DEXAIRApproved
dexamethasone sodium phosphate
Unknown Company
ophthalmic
U
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREEApproved
dexamethasone sodium phosphate
Unknown Company
injection2018

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Quince Therapeutics
Quince TherapeuticsSOUTH SAN FRANCISCO, CA
4 programs
3
Dexamethasone sodium phosphatePhase 31 trial
Dexamethasone sodium phosphatePhase 31 trial
EryDex SystemPhase 31 trial
International Ataxia Rating Scale in Younger PatientsN/A1 trial
Active Trials
NCT01942850CompletedEst. May 2014
NCT06664853TerminatedEst. Jan 2026
NCT06193200CompletedEst. Dec 2025
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Quince TherapeuticsDexamethasone sodium phosphate
Quince TherapeuticsDexamethasone sodium phosphate
Quince TherapeuticsEryDex System
Quince TherapeuticsInternational Ataxia Rating Scale in Younger Patients

Clinical Trials (4)

NCT06664853Quince TherapeuticsDexamethasone sodium phosphate

Open-Label Extension of EryDex Study IEDAT-04-2022

Start: Dec 2024Est. completion: Jan 2026
Phase 3Terminated
NCT06193200Quince TherapeuticsDexamethasone sodium phosphate

Evaluate the Neurological Effects of EryDex on Subjects With A-T

Start: Jun 2024Est. completion: Dec 2025
Phase 3Completed
NCT03563053Quince TherapeuticsEryDex System

Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study

Start: Jun 2018Est. completion: Sep 2022
Phase 3Terminated
NCT01942850Quince TherapeuticsInternational Ataxia Rating Scale in Younger Patients

International Ataxia Rating Scale in Younger Patients

Start: Aug 2013Est. completion: May 2014
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
10h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
10h ago

Director of Finance

CoMind
London, UK
10h ago

Electronics Engineering Manager

CoMind
London, UK
10h ago

Director of Information Technology

Zavation Medical Products
10h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)